Teladoc Health Future Growth
Future criteria checks 1/6
Teladoc Health is forecast to grow earnings and revenue by 53.5% and 3.6% per annum respectively. EPS is expected to grow by 52% per annum. Return on equity is forecast to be -4.5% in 3 years.
Key information
53.5%
Earnings growth rate
52.0%
EPS growth rate
Healthcare Services earnings growth | 28.8% |
Revenue growth rate | 3.6% |
Future return on equity | -4.5% |
Analyst coverage | Good |
Last updated | 29 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,870 | -81 | 321 | 477 | 13 |
12/31/2025 | 2,757 | -111 | 284 | 430 | 26 |
12/31/2024 | 2,662 | -177 | 206 | 348 | 26 |
3/31/2024 | 2,619 | -233 | 200 | 346 | N/A |
12/31/2023 | 2,602 | -220 | 194 | 350 | N/A |
9/30/2023 | 2,580 | -4,002 | 112 | 285 | N/A |
6/30/2023 | 2,531 | -4,018 | 64 | 243 | N/A |
3/31/2023 | 2,471 | -7,054 | 47 | 234 | N/A |
12/31/2022 | 2,407 | -13,660 | 17 | 189 | N/A |
9/30/2022 | 2,323 | -9,860 | 65 | 207 | N/A |
6/30/2022 | 2,234 | -9,871 | 107 | 221 | N/A |
3/31/2022 | 2,144 | -6,904 | 99 | 180 | N/A |
12/31/2021 | 2,033 | -429 | 130 | 194 | N/A |
9/30/2021 | 1,862 | -812 | -54 | -4 | N/A |
6/30/2021 | 1,629 | -763 | -92 | -49 | N/A |
3/31/2021 | 1,367 | -655 | -102 | -65 | N/A |
12/31/2020 | 1,094 | -485 | -80 | -54 | N/A |
9/30/2020 | 867 | -110 | 59 | 80 | N/A |
6/30/2020 | 716 | -95 | 46 | 61 | N/A |
3/31/2020 | 606 | -98 | 19 | 31 | N/A |
12/31/2019 | 553 | -99 | 19 | 30 | N/A |
9/30/2019 | 520 | -105 | 4 | 14 | N/A |
6/30/2019 | 493 | -108 | 2 | 11 | N/A |
3/31/2019 | 457 | -103 | -8 | 1 | N/A |
12/31/2018 | 418 | -97 | -13 | -5 | N/A |
9/30/2018 | 372 | -117 | -22 | -15 | N/A |
6/30/2018 | 330 | -125 | -44 | -37 | N/A |
3/31/2018 | 280 | -115 | -42 | -36 | N/A |
12/31/2017 | 233 | -107 | N/A | -34 | N/A |
9/30/2017 | 194 | -77 | N/A | -35 | N/A |
6/30/2017 | 157 | -75 | N/A | -38 | N/A |
3/31/2017 | 139 | -75 | N/A | -47 | N/A |
12/31/2016 | 123 | -74 | N/A | -52 | N/A |
9/30/2016 | 108 | -75 | N/A | -57 | N/A |
6/30/2016 | 96 | -58 | N/A | -59 | N/A |
3/31/2016 | 88 | -61 | N/A | -54 | N/A |
12/31/2015 | 77 | -58 | N/A | -47 | N/A |
9/30/2015 | 68 | -50 | N/A | -39 | N/A |
6/30/2015 | 59 | -42 | N/A | -24 | N/A |
3/31/2015 | 51 | -29 | N/A | -19 | N/A |
12/31/2014 | 44 | -20 | N/A | -11 | N/A |
12/31/2013 | 20 | -10 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0LDR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0LDR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0LDR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0LDR's revenue (3.6% per year) is forecast to grow faster than the UK market (3.4% per year).
High Growth Revenue: 0LDR's revenue (3.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0LDR is forecast to be unprofitable in 3 years.